<DOC>
	<DOCNO>NCT00002117</DOCNO>
	<brief_summary>To investigate appropriate zalcitabine ( dideoxycytidine ; ddC ) dose zidovudine ( AZT ) schedule use combination therapy patient HIV infection .</brief_summary>
	<brief_title>A Randomized , Open-Label Study Alternative Treatment Combinations Dideoxycytidine ( HIVID ; ddC ) Zidovudine ( AZT ) Patients With HIV Infection</brief_title>
	<detailed_description>Patients randomize one four treatment arm . ddC administer 1 2 dos every 8 hour . AZT administer 1 2 dos ( every 4 hour awake every 8 hour ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection . CD4 count 100 500 cells/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1995</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>